Q-omics provides the consensus-scored C11orf49 profile across patient tissues and cancer cell-line models. C11orf49 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, C11orf49 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, C11orf49 RNA expression shows 20,234 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, and ACC as cancer lineages where C11orf49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf49 survival associations across molecular data types. C11orf49 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf49 RNA expression–survival associations across cancer types. High C11orf49 expression shows unfavorable associations in KICH, LIHC, ACC and ESCA, but favorable associations in SCLC and BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for C11orf49 RNA expression.
This table summarizes C11orf49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C11orf49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf49 shows lower tumor expression in KICH and higher tumor expression in COAD, KIRP, LIHC, THCA and BRCA. The KICH box plot shows higher C11orf49 RNA expression in normal versus tumor tissue (log2 FC = −0.849, t-test p < 0.001).
This table shows molecular features associated with C11orf49 in patient tissues and cancer cell lines. In patient samples, C11orf49 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf49 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
